ORCHID Annual Report 2023 - Flipbook - Page 27
Post-Doctoral Researchers
Dr Lesley Katchburian
PhD, MSc, BSc (Hons), MCSP, FAPCP
Consultant Physiotherapist in Paediatric Neurodisability, Neurosciences
Great Ormond Street Hospital for Children NHS Foundation Trust
Honorary Clinical Lecturer UCL Great Ormond Street Institute of Child
Health
Lesley is a Consultant Physiotherapist and post-doctoral clinical academic
physiotherapist. Her research interests include evaluating the management of
abnormal tone in children and young people with movement disorders, using
outcome measures important to children and families. She is a Health
Education England / National Institute for Health Research (HEE/NIHR)
Clinical Doctoral Research Fellow alumni. Her PhD thesis (completed in 2023)
used mixed methods to evaluate the long-term use of Botulinum Toxin
Neurotoxin A treatment in ambulant children and young people with Cerebral
Palsy.
Lesley continues to co-lead the Physiotherapy Movement Disorders Service
and Botulinum Toxin Service at GOSH and is Physiotherapy research lead for
the Neurodisability Service. She is currently supervising NIHR PCAF students,
AHP MSc candidates at UCL and is clinical academic mentor for two NIHR
funded Doctoral students.
She continues to work with the Oxford Clinical Trials Unit as co-investigator on
two NIHR HTA funded National RCTs SPELL and ROBUST. At GOSH she also
works alongside Professor Manju Kurian, Dr Lucinda Carr, and Mr Kristian
Aquilina as a member of the research team involved with the Upstaza
(eladocagene exuparvovec) trial - an NHS England funded gene therapy trial
for children with Aromatic L-amino acid decarboxylase deficiency (AADCd).
Lesley continues to be part of the national expert panel of Getting it Right First
Time (GIRFT). Contributing to a national consultation on the use of Botulinum
Toxin A treatment in cerebral palsy. She is also on the board of the Strategic
Research Group (SRG) of the British Academy of Childhood Disability. The
SRG encourages debate and promotes research into the many outstanding
questions in childhood disability. Lesley is Chair of the paediatric British
Neurotoxin Network (pBNN) which evaluates and promotes best practice in the
field of tone management in paediatric movement disorders.
Digital Profile:
ORCiD ID: 0000-0002-7523-7083
Peer Reviewed Publications:
Katchburian L, Katchburian M (2024). Lower-limb botulinum toxin A treatment
in ambulant children with cerebral palsy. Paediatrics and Child Health, 34;8,
290 – 299. https://doi.org/10.1016/j.paed.2024.06.005
Chugh D, Cawker S, Katchburian L, Carr L, Aquilina K, Morgan S,
and Harding C (2024). Quality of Movement Changes in Ambulatory Children
with Cerebral Palsy 1 Year after Selective Dorsal Rhizotomy Physiotherapy
Canada. https://doi.org/10.3138/ptc-2023-0020
Published Abstracts:
Katchburian L, Hodgson X, Bowtell H, Oulton K, Wray J, Main E, Carr L,
Crowe B (2024)-Evaluating the effect of lower limb botulinum neurotoxin-A
treatment on improving pain in ambulant children and young people with
cerebral palsy using modified faces pain scale (mFPS) and cerebral palsy
quality of life (CPQOL) pain domain. Dev Med Child Neurol, 66: 5112. https://doi.org/10.1111/dmcn.15934
Katchburian L, Hodgson X, Carr L, Crowe B, Wray J, Oulton K, Main E,
(2024)- Evaluating the effect of lower limb botulinum neurotoxin-A treatment on
improving participation in ambulant children and young people with cerebral
palsy using the parent-reported participation environment measure for children
and
youth
(PEM-CY)
Dev
Med
Child
Neurol,
66:
5112. https://doi.org/10.1111/dmcn.15934
Conference presentations:
Katchburian L. Evaluating the effect of lower limb botulinum neurotoxin-A
treatment on improving pain in ambulant children and young people with
cerebral palsy using modified faces pain scale (mFPS) and cerebral palsy
quality of life (CPQOL) pain domain, European Academy of Childhood
Disability, Bruges, May 2024
Katchburian L. Evaluating the effect of lower limb botulinum neurotoxin-A
treatment on improving participation in ambulant children and young people
with cerebral palsy using the parent-reported participation environment
measure for children and youth (PEM-CY), European Academy of Childhood
Disability, Bruges, May 2024
Katchburian L. Using a holistic framework to review the impact of lower limb
botulinum toxin treatment for ambulant children with cerebral palsy, British
Academy of Childhood Disability, Sheffield, June 2024
